

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant To Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): June 1, 2010

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(Exact Name of Registrant
as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-15943

(Commission File Number)

06-1397316

(IRS Employer Identification No.)

**251 Ballardvale Street
Wilmington, Massachusetts**

(Address of Principal Executive Offices)

01887

(Zip Code)

Registrant's telephone number, including area code: **(978) 658-6000**

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 9.01. Financial Statements and Exhibits

<u>Exhibit No.</u>	<u>Description</u>
23.1	Consent of Deloitte Touche Tohmatsu CPA Ltd.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Charles River Laboratories, Inc.

Date: June 1, 2010

By: /s/ Matthew Daniel

Name: Matthew Daniel

Title: Deputy General Counsel and
Assistant Secretary

INDEX TO EXHIBITS

Exhibit No.	Description
23.1	Consent of Deloitte Touche Tohmatsu CPA Ltd.

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statement on Form S-3ASR (no. 333-161032) and Form S-8 (no. 333-161024, No. 333-144177, No. 333-124853, No. 333-119846, No. 333-105803, No. 333-61336 and No. 333-47768) of Charles River Laboratories International, Inc. of our reports dated April 23, 2010, relating to the consolidated financial statements and financial statement schedule of WuXi PharmaTech (Cayman) Inc, and the effectiveness WuXi PharmaTech (Cayman) Inc.'s internal control over financial reporting, appearing in the Annual Report on Form 20-F of WuXi PharmaTech (Cayman) Inc., for the year ended December 31, 2009.

/s/ Deloitte Touche Tohmatsu CPA Ltd.
Shanghai, China
June 1, 2010